Journal of Pharmaceutical Research

The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off


Hydroxyurea is an anti cancer chemotherapeutic drug .For high risk patients of essential thromocytosis (ET) , interferon and hydroxyurea are available agents in India to reduce their platelet count.

Interferon is not an attractive agent due to its parentral mode of delivery and systemic side effects. Here, we aim to evaluate the efficacy of hydroxyurea in these subset of patients to normalize their platelet counts.

This Retrospective study was conducted in the department of medical oncology and hematology at Amrita institute of medical science. We collected the data by reviewing the electronic medical records of the patients with ET in which 23 patients were seen to be at high risk for thrombotic events,Out of these 23 high risk patients 17 were females and 6 were males and belonged to the mean age of 55.17 years.

We found that 37.5 % showed complete response, 41.67 % showed partial response and 16.67 % showed no response. From this study we could observe that only 80% of patients benefited from hydroxyurea therapy and there is unmet need for an oral cytoreductive agent with good safety profile in ET.


Keywords

Hydroxyurea, Essential Thrombocytosis( ET), Cytoreductive Agent.
User
Notifications
Font Size